Рет қаралды 5,128
This video reviews Phase I and Phase II of estrogen detoxification in the liver. Estrogen is metabolized in the liver through three pathways into 2-hydroxyl, 4-hydroxyl and 16-hydroxyl estrogen.
This is known as phase I of estrogen metabolism. The 2-hydroxyl metabolite pathway is considered the best, as it creates a weak metabolite. The other two pathways, the 4-hydroxyl and 16-hydroxyl metabolite pathway, produce more potent estrogenic metabolites. The 4-hydroxyl metabolite in particular, is associated with a higher risk of breast and endometrial cancer. Phase II of estrogen metabolism involves turning the estrogens into water-soluble compounds that can easily be excreted in the urine or gut. It’s important that both Phase I and II are supported when addressing hormone metabolism.
I investigate estrogen metabolism in patients who:
• Are premenopausal patients with risk factors for breast or endometrial cancer
• Demonstrate symptoms of elevated estrogen (i.e. endometriosis, fibroids, heavy menses)
• Are taking hormone replacement therapy (estrogen) and are concerned about estrogen exposure.
To learn more about Phase III of estrogen detoxification, you can watch the video here:
*** Information in this video is provided for informational purposes only. This information is not intended as a substitute for the advice provided by your physician or other healthcare professional or any information on any product label or packaging. Do not use the information in this video for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal supplements or using any treatment for a health problem. If you have or suspect that you have a medical problem, contact your health care provider promptly.
References
1. Miao, S., Yang, F., Wang, Y., Shao, C., Zava, D. T., Ding, Q., & Shi, Y. E. (2019). 4-Hydroxy estrogen metabolite, causing genomic instability by attenuating the function of spindle-assembly checkpoint, can serve as a biomarker for breast cancer. American journal of translational research, 11(8), 4992.
2. Speroff, L., & Fritz, M. A. (Eds.). (2005). Clinical gynecologic endocrinology and infertility. lippincott Williams & wilkins.
3. Samavat, H., & Kurzer, M. S. (2015). Estrogen metabolism and breast cancer. Cancer letters, 356(2), 231-243.
4. Raftogianis, R., Creveling, C., Weinshilboum, R., & Weisz, J. (2000). Estrogen metabolism by conjugation. JNCI Monographs, 2000(27), 113-124.
5. Thomson, C. A., Chow, S. H. H., Roe, D., Wertheim, B., Chalasani, P., Altbach, M., ... & Maskaranic, G. (2017). Effect of Diindolylmethane on Estrogen-related Hormones, Metabolites and Tamoxifen Metabolism: Results of a Randomized, Placebo-controlled Trial. Cancer Epidemiology and Prevention Biomarkers, 26(3), 435-435.